B
Boltz
Emerging neolabOpen biomolecular foundation models (Boltz-1/2, BoltzGen) and a platform for small-molecule and protein design
Raised, confirmed$125M2 confirmed rounds
Valuation, confirmed—none disclosed
Valuation, reported—no open report
Founded2025Boston, MA, US
Key facts
| Field | Value | Source · checked |
|---|---|---|
| Classification | Emerging neolabPublic benefit corporation spun out of MIT CSAIL releasing open biomolecular foundation models (Boltz-1, Boltz-2, BoltzGen); $28M seed (Jan 2026) and a Pfizer collaboration | |
| Field | AI for science | |
| Founded | 2025 | sec.gov <yearOfInc> <withinFiveYears>true</withinFiveYears> <value>2025</value> </yearOfInc>checked 15 Nov 2026 |
| Headquarters | Boston, MA, USCity from the issuer address on the company's SEC Form D (Oct 2026). | sec.govchecked 15 Nov 2026 |
| Founders | Gabriele Corso, Jeremy Wohlwend, Saro Passaro | |
| Website | boltz.com | |
| Careers | boltz.com13 open roles on 15 Nov 2026 | boltz.comchecked 15 Nov 2026 |
| Profiles and work | X @boltz_bioLinkedInGitHub, 9 public repos | How links are checkedchecked 15 Nov 2026 |
Funding rounds
Boltz has raised $125M in rounds confirmed by the company, a regulator or two independent outlets. Status rules: methodology.
| Date | Round | Amount | Valuation | Investors | Status | Source · checked |
|---|---|---|---|---|---|---|
| 7 Oct 2026 | Funding round | $97.4M | — | not disclosed | Confirmed | |
| 8 Jan 2026 | Seed | $28M | — | Lead: Amplify Partners, Andreessen Horowitz, Zetta Venture Partners; Clement Delangue, Factorial Capital, Obvious Ventures | Confirmed | Boltz (via a16z) a $28 million seed round, a partnership with Pfizer, and the launch of Boltz Lab+2 more sourceschecked 15 Nov 2026 |
Notes on these rounds
- 7 Oct 2026 Funding round: Form D filed 22 Oct 2026: first sale 7 Oct 2026, $97,359,830 sold of a $119,999,991 equity offering, 18 investors. Round type and investors not stated in the filing.
- 8 Jan 2026 Seed: Announced together with a partnership with Pfizer and the launch of Boltz Lab. Clement Delangue is listed as an angel investor.
People
| Name | Role | Before | Now | Source · checked |
|---|---|---|---|---|
| Gabriele CorsoXLinkedInScholarSite | Co-founder & CEO | MIT CSAIL (PhD researcher (Barzilay lab)) | Current | |
| Jeremy WohlwendXLinkedInScholarSite | Co-founder | MIT CSAIL (PhD researcher (Barzilay lab)) | Current | genengnews.com The trio has now co-founded Boltz, as a public benefit corporation (PBC)checked 15 Nov 2026 |
| Saro PassaroXLinkedIn | Co-founder | MIT CSAIL (Research scientist (Barzilay lab)) | Current | genengnews.com The trio has now co-founded Boltz, as a public benefit corporation (PBC)checked 15 Nov 2026 |
Professional facts from public sources only. How people records are handled.
What it has shipped
| Name | Kind | Date | Open weights | Source · checked |
|---|---|---|---|---|
| Boltz-1 | model | Nov 2024 | Yes | genengnews.com In November 2024, Boltz-1 debuted as a fully commercially available AI modelchecked 15 Nov 2026 |
| Boltz-2 | model | Jun 2025 | Yes | a16z.news we demonstrated that frontier structure prediction models, combined with large-scale supervision, can push binding affinity prediction to unprecedented accuracychecked 15 Nov 2026 |
| BoltzGen | model | Yes | a16z.news a protein design model and agent capable of generating binders to arbitrary targetschecked 15 Nov 2026 | |
| Boltz Lab | product | 8 Jan 2026 | No | techrepublic.com also launched Boltz Lab and its first agents for small-molecule and protein designchecked 15 Nov 2026 |
| BoltzMol-1 | model | No | boltz.bio A step change in small-molecule screening and hit discovery, experimentally validated at scale.checked 15 Nov 2026 |
Work at Boltz, or see something wrong? Update this profile with a public source. How corrections work.